Kailera Therapeutics, Inc. (KLRA)
$10.77-4.94%Close
SELL
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $1.4B
- Beta
- 0.50
- P/E (TTM)
- -6.12
- Short % float
- 9.72%
- Days to cover
- 5.6
- SI change
- +45.6%
- 1W
- -0.55%
- 1M
- -21.67%
- vs SPY 1W
- -0.42%
- vs SPY 1M
- -24.18%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 19
- VALUE
- 12
- GROWTH
- 47
- GARP
- 6
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-33.2%
REV YoY-
ROE-55.4%
EPS YoY-
ROA-15.7%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-6.12
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B0.98
P/FCF-
EV/EBITDA-6.51
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E0.91
ALTMAN Z-
CURR RATIO11.11
ND/EBITDA-
BETA0.50
Company news
FAQ
- What is LOPJLB’s current signal on KLRA?
- LOPJLB’s latest quantitative signal on Kailera Therapeutics, Inc. (KLRA) is SELL. Signals are updated daily.
- What market regime is KLRA in?
- LOPJLB classifies each ticker into BULL, RECOVERY, BEAR, or CRISIS regimes using a Hidden Markov Model.
- What does Kailera Therapeutics, Inc. (KLRA) do?
- Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an ora…